Skip to Main Content

STAT’s Matthew Herper struck an industry nerve when he wrote that the drug development industry is “not prepared for the next wave of biotech innovation.”

His report ends on a somewhat dismal note: the industry is long on diagnosis (clinical development is too expensive) and short on cures.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


Create a display name to comment

This name will appear with your comment